Lobaplatin is the third generation of platinum antineoplastic   drugs, originally  researched   by the German ASTA company. In 2003, Hainan Chang 'an   International Pharmaceutical Co., Ltd.    successfully transforms intellectual property rights of Lobaplatin to   China, approved for marketing in China in 2005. Lobaplatin  has alkylation and it is a generalized   alkylating agent. It has definite cytotoxicity for a variety of animal and   human tumor cell lines, and its pharmacological effects are similar to those   of cis-platinum.   Clinically, Lobaplatin for Injection mainly used in the treatment of breast   cancer, small cell lung cancer and chronic myeloid leukemia.

The   clinical administration features of Lobaplatin for Injection are as bellows:
  1, Lactic acid platinum, water solubility, good stability;
  2, Anticancer spectrum similar to cis-platinum,   anticancer activity quiet similar to cis-platinum   and more stronger than carboplatin, and no cross-resistance with other   platinum drugs;

3, No obvious nephrotoxicity, ototoxicity and   neural toxicity, and gastrointestinal tract toxicity is lighter;
  4, Rapid clearance through the kidney, not easily be accumulated in the body,   short duration of effect and less toxic side effects.

       Lobaplatin is featured by  its chemical structure, physical and   chemical properties and pharmacokinetics, etc.,  and thus bears the advantage of "high   efficiency, low toxicity and no cross-resistance”. Those advantages are   gradually validated and revealed in clinical practice.

Further   research and development of the treatment in refractory ovarian cancer, malignant   coelomic effusion chemotherapy, advanced esophageal cancer, HCC with TACE(Transhepatic   Arterial Chem Otherapy and Embolization), etc.,  are urgently needed for clinical treatment,   and they are also have important social and economic value.

Development process:

Innovative original research of Germany ASTA   Medica;

Hainan Changan International Pharmaceuticals   Co., Ltd. successfully transforms the intellectual property rights of   Lobaplatin to China in September 2003, obtained the exclusive patent :   "Naropa platinum trihydrate and    its preparation and application".(ZL94106670.3);

Approved the specification of 50mg by SFDA   in  September 2005 to put into the   market(H20050308);

“ Research   and Development of Lobaplatin” awarded the project fund of the eleventh five-year   plan and 863 plan in April 2007(Project number:   2006AA020608);

Approved   the specification of 10mg by SFDA in    March 2008 to put into the market. (H20050308);

Selected   as national health care products in November 2009;

"Secondary Research and Development of   Lobaplatin as a Class I Antineoplastic New Drug” obtained special project   fund for science and technology major projects in Guizhou province in July   2011. [Project number:   Guizhou branch and traditional Chinese medicine (TCM) word (2011)5068]